ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

Methotrexate Halt Feasible in Some Etanercept RA Responders

David Douglas  |  September 21, 2015

NEW YORK (Reuters Health)—Certain rheumatoid arthritis (RA) patients doing well on etanercept and methotrexate may be able to quit the latter agent if they have tolerability problems, according to an open-label Canadian study. In a Sept. 11 online paper in Rheumatology, Dr. Boulos Haraoui, of the University of Montreal, and colleagues noted that although combination…

Depression & Anxiety Linked to Poor Rheumatoid Arthritis Outcomes

Rob Goodier  |  September 18, 2015

NEW YORK (Reuters Health)—Rheumatoid arthritis patients with depression and anxiety symptoms may have worse outcomes and poorer response to prednisolone, a secondary analysis of the CARDERA trial has found. “The strength of association between depression/anxiety and disease activity outcomes and treatment response warrants routine screening,” the study’s lead author Faith Matcham at King’s College London…

Poverty May Increase Odds of Repeat Hospitalizations

Lisa Rapaport  |  September 16, 2015

(Reuters Health)—When patients are hospitalized more than once in the same month, it may have more to do with their income or education levels than the quality of care they received, a U.S. study suggests. Perhaps unsurprisingly, patients 85 and older are more likely to return to the hospital within 30 days of being sent…

XenoPort’s Psoriasis Drug Found Effective in Phase 2 Trial

Reuters Staff  |  September 15, 2015

(Reuters)—Drug developer XenoPort Inc. said on Tuesday its experimental drug was effective in treating psoriasis, sending its shares up 19% in premarket trading. The oral drug met the main goal in a phase 2 trial of patients with moderate-to-severe chronic plaque-type psoriasis, the company said. XenoPort said it expected to start late-stage trials next year…

U.S. Bans Another Indian Drug Plant over Production Quality

Reuters Staff  |  September 15, 2015

MUMBAI (Reuters)—The U.S. Food and Drug Administration (FDA) has banned imports from another India-based drug manufacturing plant over quality control concerns, making it the 10th site in the country this year to face such action. The FDA’s import alert on Mumbai-based Polydrug Laboratories Pvt Ltd’s Ambernath manufacturing plant comes two months after Canada banned the…

ACR Releases Two New Publications

American College of Rheumatology  |  September 15, 2015

Two new ACR publications, created in collaboration with the European League Against Rheumatism, aim to improve the treatment of patients with polymyalgia rheumatica (PMR) and introduce new classification criteria for gout…

Serum IGF-1 Tied to Fracture Risk in Elderly Women

David Douglas  |  September 14, 2015

NEW YORK (Reuters Health)—A Dutch study confirms that reduced serum levels of insulin-like growth factor-1 (IGF-1) are associated with increased fracture risk in elderly women, but not men. In an Aug. 31 online paper in the Journal of Clinical Endocrinology & Metabolism, Dr. N.C. van Varsseveld, of VU University Medical Center, Amsterdam, and colleagues noted that…

More Evidence Dexamethasone Speeds Recovery in Kids with Septic Arthritis

Will Boggs, MD  |  September 11, 2015

NEW YORK (Reuters Health)—Adding to earlier evidence, a new study finds kids with septic arthritis who are treated with dexamethasone recover faster. “We expected these results based on our previous randomized double-blind controlled study,” Dr. Itay Fogel from Schneider Children’s Medical Center of Israel and Tel Aviv University told Reuters Health by email. “However, the…

Hamstrung by Red Tape, Hospital Operators Buy Their Way into India

Aditya Kalra & Aditi Shah  |  September 11, 2015

NEW DELHI (Reuters)—For nearly two years, Parkway Pantai has delayed the opening of its 450-bed India hospital, the Singapore-based medical firm’s bid to cash in on one of Asia’s fastest growing private healthcare markets, as it waited for the necessary permits. Parkway, a unit of the world’s second largest healthcare group by market value IHH…

Pfizer Loses UK Patent Case over Use of Lyrica Drug for Pain

Ben Hirschler  |  September 10, 2015

LONDON (Reuters)—Pfizer suffered a major setback in Britain on Thursday when the High Court in London ruled that claims of patent protection for the use of its $5 billion-a-year drug Lyrica as a pain treatment were invalid. Lyrica, known generically as pregabalin, was originally developed for epilepsy. However, further research showed it could also help patients…

  • « Previous Page
  • 1
  • …
  • 85
  • 86
  • 87
  • 88
  • 89
  • …
  • 98
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences